Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 3Other hematologic neoplasm 1CNS 1

Conditions

Glioblastoma 527Brain Neoplasms 415Glioma 343Astrocytoma 239Central Nervous System Neoplasms 201Neuroblastoma 195Gliosarcoma 163Oligodendroglioma 149Medulloblastoma 118Neoplasms 113Ependymoma 72Recurrence 70Breast Neoplasms 69Sarcoma 65Melanoma 62Carcinoma, Non-Small-Cell Lung 58Osteosarcoma 57Diffuse Intrinsic Pontine Glioma 48Wilms Tumor 47Familial ependymoma 47Lymphoma 46Neoplasm Metastasis 45Optic Nerve Glioma 44Rhabdomyosarcoma 42Rhabdoid Tumor 42Lung Neoplasms 42Choroid Plexus Neoplasms 42Neuroectodermal Tumors, Primitive 38Meningeal Carcinomatosis 38Ovarian Neoplasms 37

Interventions

fludarabine 1Leukapheresis 1Cyclophosphamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Cytokine Release Syndrome × CNS × Clear all
NCT02761915 2021-08-17

A Phase I Trial of Anti-GD2 T-cells (1RG-CART)

Cancer Research UK

Phase 1 Completed
17 enrolled 17 charts
CNS

Cytokine Release Syndrome, Neuroblastoma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡